Clinical detection of blood meropenem concentration based on fluorescent probe molecules and equipment development

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300071468

Enrollment

Unknown

Registered

2023-05-16

Start date

2023-06-01

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infection

Interventions

HPLC group:None

fluorescent probe group:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. ICU patients and Age >= 18; 2. Application of meropenem 3. Sign the informed consent voluntarily

Exclusion criteria

Exclusion criteria: 1. Reject the experimental patients; 2. The final data collected is incomplete due to various reasons;

Design outcomes

Primary

Measure	Time frame
Meropenem drug concentration;Meropenem drug concentration;Meropenem drug concentration;Meropenem drug concentration;	—

Countries

China

Contacts

Public ContactYanfei Mao, Rongrong Ren, Lixia Li

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,

maoyanfei@xinhuamed.com.cn+86 21 2507 7825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026